Skip to main content
Publications
Mayen Herrera E, Chiranjeevi P, Stanford R, Njue A, Lyall M, Nuabor W, D'Souza V, Dubucq H, Moola S. Clinical burden of patients with moderate-to-severe chronic obstructive pulmonary disease: a focused literature review. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S549-50. doi: 10.1016/j.jval.2023.09.2953
Mayen Herrera E, Chiranjeevi P, Stanford R, Njue A, Lyall M, Nuabor W, D'Souza V, Dubucq H, Moola S. Economic burden of patients in the United States with moderate-to-severe chronic obstructive pulmonary disease: a focused literature review. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplment):S553. doi: 10.1016/j.jval.2023.09.2970
Halsby K, Gildea L, Colosia A, Madhava H, Erber W, Angulo F, Pilz A, Schley K, Moisi J, Sellner J. The clinical spectrum of TBE infections in adult and paediatric populations in Europe: a systematic review. Poster presented at the International Symposium on Tick-Borne Pathogens and Disease (ITPD) 2023; October 24, 2023. Vienna, Austria.
Douillard JY, Cella D, Natale R, Lynch TL, Lee C, Carbone D, Kay A, Wolf M M, Heyes AE, Ward J. Clinically meaningful improvement in disease-related symptoms by 'gefitinib' (Iressa, ZD1839) in patients with advanced non-small cell lung cancer: relationship between lung cancer subscale scores and radiographic response and survival. Presented at the European Cancer Conference 12; September 2003; September 2003. Copenhagen, Denmark.
LoRusso PM, Herbst RS, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Maddox A, Rothenberg ML, Small EJ, Rubin EH, Feyereislova A, Heyes A, Averbuch SD, Ochs J, Baselga J. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res. 2003 Jun 1;9(6):2040-8.
Cella D, Natale R, Lynch T T, Lee C, Carbone D, Douillard JY, Kay A, Wolf M, Heyes AE, Ward J. Disease-related symptoms in advanced nsclc as measured by the lung cancer subscale (LCS) of the fact-l questionnaire: clinically meaningful improvement with gefitinib (Iressa, ZD1839). Presented at the American Society of Clinical Oncology; May 2003. Chicago, IL.
Trump DL, Wilding G, Miller K, Small E, Soulie P, Trachtenberg J, Raabe N, Heyes AE, Das-Gupta A. Pilot trials of ZD1839 ('Iressa'), an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor, in combination with mitoxantrone/prednisolone or docetaxel/estramustine in patients with hormone-refractory prostate cancer. Presented at the American Urology Association; April 2003. Chicago, IL.